Non-alcoholic Fatty Liver Disease
-
Subject Areas on Research
-
A Peripheral Blood DNA Methylation Signature of Hepatic Fat Reveals a Potential Causal Pathway for Nonalcoholic Fatty Liver Disease.
-
A Western diet induced NAFLD in LDLR(-/)(-) mice is associated with reduced hepatic glutathione synthesis.
-
A critical role for ChREBP-mediated FGF21 secretion in hepatic fructose metabolism.
-
A longer duration of estrogen deficiency increases fibrosis risk among postmenopausal women with nonalcoholic fatty liver disease.
-
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.
-
A targeted analysis reveals relevant shifts in the methylation and transcription of genes responsible for bile acid homeostasis and drug metabolism in non-alcoholic fatty liver disease.
-
Accumulation of duct cells with activated YAP parallels fibrosis progression in non-alcoholic fatty liver disease.
-
Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis.
-
American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases.
-
Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and Liver Histology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis.
-
Association between puberty and features of nonalcoholic fatty liver disease.
-
Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease.
-
Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease.
-
Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
-
Biomarkers of NAFLD progression: a lipidomics approach to an epidemic.
-
Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
-
Branched chain amino acid transaminase 1 (BCAT1) is overexpressed and hypomethylated in patients with non-alcoholic fatty liver disease who experience adverse clinical events: A pilot study.
-
CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis.
-
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.
-
Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease.
-
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.
-
Choline intake in a large cohort of patients with nonalcoholic fatty liver disease.
-
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
-
Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome.
-
Comment on: impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012.
-
Comparison of the frequency of coronary artery disease in alcohol-related versus non-alcohol-related endstage liver disease.
-
Correction: Mouse Models of Diet-Induced Nonalcoholic Steatohepatitis Reproduce the Heterogeneity of the Human Disease.
-
Correlation of vitamin E, uric acid, and diet composition with histologic features of pediatric NAFLD.
-
Costaining for keratins 8/18 plus ubiquitin improves detection of hepatocyte injury in nonalcoholic fatty liver disease.
-
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
-
Current status of fibrosis markers.
-
DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis.
-
De Novo and Recurrence of Nonalcoholic Steatohepatitis After Liver Transplantation.
-
Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum.
-
Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage.
-
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
-
Dietary and commercialized fructose: Sweet or sour?
-
Direct effects of thyroid hormones on hepatic lipid metabolism.
-
Divergent effects of glucose and fructose on hepatic lipogenesis and insulin signaling.
-
Editorial: blood biomarkers for advanced liver fibrosis in non-alcoholic fatty liver disease-not a simple choice?
-
Editorial: diabetes, obesity and clinical inertia-the recipe for advanced NASH. Authors' reply.
-
Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension.
-
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
-
Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21.
-
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
-
Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials.
-
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.
-
Fibrosis in nonalcoholic Fatty liver disease: mechanisms and clinical implications.
-
From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world.
-
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease.
-
Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis.
-
Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
-
Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits.
-
HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease.
-
Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human nonalcoholic fatty liver disease.
-
Hedgehog pathway and pediatric nonalcoholic fatty liver disease.
-
Hepatic FTO expression is increased in NASH and its silencing attenuates palmitic acid-induced lipotoxicity.
-
Hepatic HKDC1 Expression Contributes to Liver Metabolism.
-
Hepatic Lipid Catabolism via PPARα-Lysosomal Crosstalk.
-
Hepatic R2* is more strongly associated with proton density fat fraction than histologic liver iron scores in patients with nonalcoholic fatty liver disease.
-
Hepatic gene expression profiles differentiate presymptomatic patients with mild versus severe nonalcoholic fatty liver disease.
-
Hepatocyte Notch activation induces liver fibrosis in nonalcoholic steatohepatitis.
-
High circulatory leptin mediated NOX-2-peroxynitrite-miR21 axis activate mesangial cells and promotes renal inflammatory pathology in nonalcoholic fatty liver disease.
-
Histologic Findings of Advanced Fibrosis and Cirrhosis in Patients With Nonalcoholic Fatty Liver Disease Who Have Normal Aminotransferase Levels.
-
Hormone signaling and fatty liver in females: analysis of estrogen receptor α mutant mice.
-
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
-
Implication of gut microbiota in nonalcoholic fatty liver disease.
-
Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.
-
Increasing Dietary Medium-Chain Fatty Acid Ratio Mitigates High-fat Diet-Induced Non-Alcoholic Steatohepatitis by Regulating Autophagy.
-
Inhibiting Interleukin 11 Signaling Reduces Hepatocyte Death and Liver Fibrosis, Inflammation, and Steatosis in Mouse Models of Nonalcoholic Steatohepatitis.
-
Iron deficiency in patients with nonalcoholic Fatty liver disease is associated with obesity, female gender, and low serum hepcidin.
-
Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis.
-
Linearity, Bias, and Precision of Hepatic Proton Density Fat Fraction Measurements by Using MR Imaging: A Meta-Analysis.
-
Liver Transplantation for Nonalcoholic Steatohepatitis: Pathophysiology of Recurrence and Clinical Challenges.
-
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib.
-
Low and High Birth Weights Are Risk Factors for Nonalcoholic Fatty Liver Disease in Children.
-
Low-Dose Levothyroxine Reduces Intrahepatic Lipid Content in Patients With Type 2 Diabetes Mellitus and NAFLD.
-
Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.
-
M1 polarization bias and subsequent nonalcoholic steatohepatitis progression is attenuated by nitric oxide donor DETA NONOate via inhibition of CYP2E1-induced oxidative stress in obese mice.
-
MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease.
-
Mechanisms of disease progression in NASH: new paradigms.
-
Metabolic liver disease - what's in a name?
-
Metabolomic analysis shows differential hepatic effects of T2 and T3 in rats after short-term feeding with high fat diet.
-
Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis.
-
Mitigation of autophagy ameliorates hepatocellular damage following ischemia-reperfusion injury in murine steatotic liver.
-
Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease.
-
NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment.
-
NAFLD and extrahepatic cancers: have a look at the colon.
-
NAFLD is associated with methylation shifts with relevance for the expression of genes involved in lipoprotein particle composition.
-
NAFLD, NASH and liver cancer.
-
NASH in HIV.
-
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
-
NKT-associated hedgehog and osteopontin drive fibrogenesis in non-alcoholic fatty liver disease.
-
No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
-
Nonalcoholic Fatty Liver Disease Among Individuals with HIV Mono-infection: A Growing Concern?
-
Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.
-
Nonalcoholic Fatty Liver Disease and the Gut Microbiome.
-
Nonalcoholic Fatty Liver Disease.
-
Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation.
-
Nonalcoholic Steatohepatitis Is Associated With Liver-Related Outcomes and All-Cause Mortality in Chronic Hepatitis B.
-
Nonalcoholic Steatohepatitis.
-
Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context.
-
Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis.
-
Nonalcoholic fatty liver disease: another leap forward.
-
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.
-
Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease.
-
Novel Transcriptional Mechanisms for Regulating Metabolism by Thyroid Hormone.
-
Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease.
-
Obese humans with nonalcoholic fatty liver disease display alterations in fecal microbiota and volatile organic compounds.
-
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
-
Osteopontin is a proximal effector of leptin-mediated non-alcoholic steatohepatitis (NASH) fibrosis.
-
Osteopontin is induced by hedgehog pathway activation and promotes fibrosis progression in nonalcoholic steatohepatitis.
-
Outcomes of Liver Transplantation Among Older Recipients With Nonalcoholic Steatohepatitis in a Large Multicenter US Cohort: the Re-Evaluating Age Limits in Transplantation Consortium.
-
PAR2 controls cholesterol homeostasis and lipid metabolism in nonalcoholic fatty liver disease.
-
Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma.
-
Pathogenesis of Nonalcoholic Steatohepatitis.
-
Patient Sex, Reproductive Status, and Synthetic Hormone Use Associate With Histologic Severity of Nonalcoholic Steatohepatitis.
-
Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life.
-
Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial.
-
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.
-
Posttransplant Outcome of Lean Compared With Obese Nonalcoholic Steatohepatitis in the United States: The Obesity Paradox.
-
Predictors of De Novo Nonalcoholic Fatty Liver Disease After Liver Transplantation and Associated Fibrosis.
-
Prolonged Delirium With Catatonia Following Orthotopic Liver Transplant Responsive to Memantine.
-
Purinergic receptor X7 is a key modulator of metabolic oxidative stress-mediated autophagy and inflammation in experimental nonalcoholic steatohepatitis.
-
Purinergic receptor X7 mediates leptin induced GLUT4 function in stellate cells in nonalcoholic steatohepatitis.
-
Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis.
-
Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.
-
Regional anthropometric measures and hepatic fibrosis in patients with nonalcoholic Fatty liver disease.
-
Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study.
-
Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease.
-
Relationship between resolution of non-alcoholic steatohepatitis and changes in lipoprotein sub-fractions: a post-hoc analysis of the PIVENS trial.
-
Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
-
Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism.
-
Reply to Kim et al.
-
Reply.
-
Reply.
-
Reply.
-
Reply: To PMID 24849310.
-
Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD.
-
Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD.
-
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
-
Review article: the impact of liver-directed therapies on the atherogenic risk profile in non-alcoholic steatohepatitis.
-
Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
-
Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
-
Role of Hedgehog Signaling Pathway in NASH.
-
Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations.
-
Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis.
-
S-Nitrosoglutathione Reductase Dysfunction Contributes to Obesity-Associated Hepatic Insulin Resistance via Regulating Autophagy.
-
Screening for metabolic and reproductive complications in obese children and adolescents.
-
Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps.
-
Sex Hormone Relations to Histologic Severity of Pediatric Nonalcoholic Fatty Liver Disease.
-
Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis.
-
Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation.
-
Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
-
Sugar sweetened beverages and fatty liver disease: Rising concern and call to action.
-
Systematic integrative analysis of gene expression identifies HNF4A as the central gene in pathogenesis of non-alcoholic steatohepatitis.
-
Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers.
-
Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development.
-
TRPV4 activation of endothelial nitric oxide synthase resists nonalcoholic fatty liver disease by blocking CYP2E1-mediated redox toxicity.
-
Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis.
-
Testing for Nonalcoholic Fatty Liver Disease.
-
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
-
The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials.
-
The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options.
-
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
-
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
-
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.
-
The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
-
The hedgehog pathway in nonalcoholic fatty liver disease.
-
The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.
-
The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota.
-
Thyroid Hormones and Thyromimetics: A New Approach to Nonalcoholic Steatohepatitis?
-
Towards a definite mouse model of NAFLD.
-
Transplant Outcomes in Older Patients With Nonalcoholic Steatohepatitis Compared to Alcohol-related Liver Disease and Hepatitis C.
-
Treatment response in the PIVENS trial is associated with decreased Hedgehog pathway activity.
-
Upregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis.
-
Validation of Serum Test for Advanced Liver Fibrosis in Patients With Nonalcoholic Steatohepatitis.
-
Vibration-Controlled Transient Elastography to Assess Fibrosis and Steatosis in Patients With Nonalcoholic Fatty Liver Disease.
-
Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
-
Vitamin D is Not Associated With Severity in NAFLD: Results of a Paired Clinical and Gene Expression Profile Analysis.
-
Why we need to curb the emerging worldwide epidemic of nonalcoholic fatty liver disease.
-
Keywords of People